Veeva RIM Boosts Market Entry Speed for Over 450 Companies in Healthcare
In a significant leap within the biopharmaceutical industry, Veeva Systems has announced that over 450 enterprises, integrating 19 of the top 20 biopharmaceutical companies, have commenced utilizing Veeva RIM (Regulatory Information Management) to enhance their market entry strategies. This innovative platform serves as a unified hub for managing regulatory information, setting a new standard for efficiency and collaboration among global health authorities.
Veeva RIM’s growth is propelled by ongoing innovations aimed at improving connectivity and collaboration. Recently, Veeva Systems formed strategic partnerships with Accumulus Technologies and DNAnexus. These alliances are designed to facilitate seamless integration with a multitude of health authority platforms, which significantly augments both efficiency and compliance. As Marc Gabriel, Vice President of Regulatory at Veeva, notes, “Regulatory teams are adopting Veeva's product innovations to continuously improve efficiency and reduce cycle times.” This streamlined approach not only accelerates the market launch of new treatments but also promotes enhanced collaboration among various stakeholders across the globe.
Companies leveraging Veeva RIM are better positioned to optimize processes throughout the regulatory lifecycle. Notably, with the implementation of Veeva Submissions Publishing, over 85 organizations are now utilizing continuous publishing to lessen revision workloads and eliminate bottlenecks, which previously delayed submission timelines. This advancement is critical for the rapid introduction of essential pharmaceuticals amidst a dynamic regulatory landscape.
Accumulus Technologies, through its strategic partnership with Veeva, aims to connect its platform to Veeva RIM, thereby enabling increased interoperability. Francisco Nogueira, CEO of Accumulus, asserts, “By modernizing the manner in which information is shared in real time with our expanding network of over 70 regulatory agencies worldwide, we can facilitate regulatory submissions that help our mutual clients deliver treatments to patients more swiftly.” This commitment to improving the efficiency of regulatory processes is echoed in the broader objectives of both companies involved.
Furthermore, the integration of DNAnexus’s Trusted Regulatory Spaces (TRS) with Veeva RIM is set to offer cutting-edge data-sharing capabilities. Thomas Laur, CEO of DNAnexus, highlights that this collaboration will foster inter-agency cooperation and expedite product approvals across regulatory frameworks.
Veeva RIM operates on a cloud-based platform, effectively consolidating global regulatory processes and enhancing the development cloud for various products in clinical, quality, regulatory, and safety sectors. It represents a significant technological advancement that caters to the growing demands of the life sciences industry.
Veeva Systems stands as a pillar in delivering industry-specific cloud solutions, catering to the life sciences sector with comprehensive software, data, and commercial consulting services. With a commitment to innovation and customer success, Veeva collaborates with over 1,500 clients, including leading biopharmaceutical corporations and emerging biotechs. By aligning the interests of various stakeholders such as customers, employees, and shareholders, Veeva continues to reaffirm its role as a key player in the biopharmaceutical landscape.
For those interested in expanding their understanding of Veeva RIM, additional resources can be accessed at Veeva.com/eu/RIM, where insights into the transformative power of this regulatory management tool await.
In conclusion, the adoption of Veeva RIM by an expansive array of biopharmaceutical companies not only signifies a marked improvement in regulatory management but also showcases the collective efforts to foster better health outcomes through efficient market access strategies. As the landscape of healthcare continues to evolve, Veeva systems are positioned to lead the charge in regulatory efficacy and patient support.
Veeva RIM’s growth is propelled by ongoing innovations aimed at improving connectivity and collaboration. Recently, Veeva Systems formed strategic partnerships with Accumulus Technologies and DNAnexus. These alliances are designed to facilitate seamless integration with a multitude of health authority platforms, which significantly augments both efficiency and compliance. As Marc Gabriel, Vice President of Regulatory at Veeva, notes, “Regulatory teams are adopting Veeva's product innovations to continuously improve efficiency and reduce cycle times.” This streamlined approach not only accelerates the market launch of new treatments but also promotes enhanced collaboration among various stakeholders across the globe.
Companies leveraging Veeva RIM are better positioned to optimize processes throughout the regulatory lifecycle. Notably, with the implementation of Veeva Submissions Publishing, over 85 organizations are now utilizing continuous publishing to lessen revision workloads and eliminate bottlenecks, which previously delayed submission timelines. This advancement is critical for the rapid introduction of essential pharmaceuticals amidst a dynamic regulatory landscape.
Accumulus Technologies, through its strategic partnership with Veeva, aims to connect its platform to Veeva RIM, thereby enabling increased interoperability. Francisco Nogueira, CEO of Accumulus, asserts, “By modernizing the manner in which information is shared in real time with our expanding network of over 70 regulatory agencies worldwide, we can facilitate regulatory submissions that help our mutual clients deliver treatments to patients more swiftly.” This commitment to improving the efficiency of regulatory processes is echoed in the broader objectives of both companies involved.
Furthermore, the integration of DNAnexus’s Trusted Regulatory Spaces (TRS) with Veeva RIM is set to offer cutting-edge data-sharing capabilities. Thomas Laur, CEO of DNAnexus, highlights that this collaboration will foster inter-agency cooperation and expedite product approvals across regulatory frameworks.
Veeva RIM operates on a cloud-based platform, effectively consolidating global regulatory processes and enhancing the development cloud for various products in clinical, quality, regulatory, and safety sectors. It represents a significant technological advancement that caters to the growing demands of the life sciences industry.
Veeva Systems stands as a pillar in delivering industry-specific cloud solutions, catering to the life sciences sector with comprehensive software, data, and commercial consulting services. With a commitment to innovation and customer success, Veeva collaborates with over 1,500 clients, including leading biopharmaceutical corporations and emerging biotechs. By aligning the interests of various stakeholders such as customers, employees, and shareholders, Veeva continues to reaffirm its role as a key player in the biopharmaceutical landscape.
For those interested in expanding their understanding of Veeva RIM, additional resources can be accessed at Veeva.com/eu/RIM, where insights into the transformative power of this regulatory management tool await.
In conclusion, the adoption of Veeva RIM by an expansive array of biopharmaceutical companies not only signifies a marked improvement in regulatory management but also showcases the collective efforts to foster better health outcomes through efficient market access strategies. As the landscape of healthcare continues to evolve, Veeva systems are positioned to lead the charge in regulatory efficacy and patient support.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.